Novartis Quarterly Financial Results

Q2 2021 results - Wednesday, July 21, 2021

Media release

English (PDF 0.4 MB) Deutsch (PDF 0.4 MB) Français (PDF 0.4 MB)

Interim financial report (PDF 0.5 MB)

Watch the webcast

Download the podcast (MP3 45 MB)

Read the presentation transcript

Download the interactive presentation (PDF 4.5 MB)

Novartis ESG Update - July 22, 2021 (PDF 1.8 MB)

Key figures1

  Q2 2021
(USD m)
Q2 2020
(USD m)
% change
(USD/cc)
Net sales 12,956 11,347 14 (cc: 9)
Operating income 3,479 2,352 48 (cc: 41)
Net income 2,895 1,867 55 (cc: 49)
EPS (USD) 1.29 0.82 57 (cc: 52)
Free cash flow 4,235 3,631 17

Core
     
Operating income 4,345 3,669 18 (cc: 13)
Net income 3,716 3,108 20 (cc: 14)
EPS (USD) 1.66 1.36 22 (cc: 16)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 48 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Q1 2021 results - Tuesday, April 27, 2021

Media release

English (PDF 0.2 MB) Deutsch (PDF 0.2 MB) Français (PDF 0.2 MB)

Interim financial report (PDF 0.4 MB)

Watch the webcast

Read the presentation transcript

Download the podcast (MP3 40 MB)

Download the interactive presentation (PDF 7.2 MB)

Novartis ESG Update - April 28, 2021 (PDF 0.3 MB)

Key figures1 Q1 2021
(USD m)
Q1 2020
(USD m)
% change
(USD/cc)
Net sales 12,411 12,283 1 (cc: -2)
Operating income 2,415 2,744 -12 (cc: -14)
Net income 2,059 2,173 -5 (cc: -7)
EPS (USD) 0.91 0.96 -5 (cc: -6)
Free cash flow 1,597 2,021 -21

Core
     
Operating income 3,957 4,177 -5 (cc: -8)
Net income 3,413 3,549 -4 (cc: -6)
EPS (USD) 1.52 1.56 -3 (cc: -5)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 36 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Annual results and Q4 2020
Tuesday, January 26, 2021

Media release

English (PDF 0.2 MB) Deutsch (PDF 0.2 MB) Français (PDF 0.2 MB)

Condensed financial report (PDF 0.9 MB)

Watch the webcast

Read the presentation transcript

Download the podcast (MP3 45 MB)

Download the presentation (PDF 3.6 MB)

Access our interactive slide deck (PDF 12 MB)

Novartis ESG Update - January 27, 2021 (PDF 0.5 MB)

Key figures2 Continuing operations1
  Q4 2020
(USD m)
Q4 2019
(USD m)
% change
(USD/cc)
Net sales 12,770 12,403 3 (cc: 1)
Operating income 2,644 1,823 45 (cc: 51)
Net income 2,099 1,129 86 (cc: 93)
EPS (USD) 0.92 0.50 84 (cc: 93)
Free cash flow 3,342 3,488 -4

Core
     
Operating income 3,501 3,462 1 (cc: 2)
Net income 3,034 2,985 2 (cc: 3)
EPS (USD) 1.34 1.32 2 (cc: 3)
  1. Refers to continuing operations as defined on page 43 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions.
  2. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Q3 2020 results - Tuesday, October 27, 2020

Media release

English (PDF 0.2 MB) Deutsch (PDF 0.2 MB) Français (PDF 0.3 MB)

Interim financial report (PDF 0.8 MB)

Watch the webcast

Read the presentation transcript

Download the podcast (MP3 41 MB)

Download the presentation (PDF 2.7 MB)

Novartis ESG Update - October 28, 2020 (PDF 0.5 MB)

  Continuing operations1
Key figures2 Q3 2020
(USD m)
Q3 2019
(USD m)
% change
(USD/cc)
Net sales 12,259 12,172 1 (cc: 0)
Operating income 2,412 2,358 2 (cc: 9)
Net income 1,932 2,041 -5 (cc: 0)
EPS (USD) 0.85 0.90 -6 (cc: 0)
Free cash flow 2,697 3,968 -32

Core
     
Operating income 4,069 3,748 9 (cc: 11)
Net income 3,467 3,212 8 (cc: 10)
EPS (USD) 1.52 1.41 8 (cc: 9)
  1. Refers to continuing operations as defined on page 42 of the Condensed Interim Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions.
  2. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 54 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

 

Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.